Vapotherm, Inc. (NYSE:VAPO) is reporting second quarter earnings results on Tuesday 4th August 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.39 per share.
For the full year, analysts predict revenues of $ 90.46 million, while looking forward to loss of $ 2.19 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 52.90 million ~ $ 54.50 million
Click Here For More Historical Outlooks Of Vapotherm, Inc.
Previous Quarter Performance
Vapotherm, Inc. revealed loss for the first quarter of $ 0.66 per share, from the revenue of $ 19.11 million. The quarterly revenues improved 59.52 percent compared with the same quarter last year. Street analysts expected Vapotherm, Inc. to report loss of $ 0.56 per share on revenue of $ 18.90 million for the first quarter. The bottom line results missed street analysts by $ 0.1 or 17.86 percent, at the same time, top line results outshined analysts by $ 0.21 million or 1.11 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Vapotherm, Inc.
Stock Performance
According to the previous trading day, closing price of VAPO was $ 52.94, representing a 671.72 % increase from the 52 week low of $ 6.86 and a 2.23 % decrease over the 52 week high of $ 54.15.
The company has a market capital of $ 1.15 billion and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”VAPO” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Vapotherm, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.vapotherm.com
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit and Q50 compressor; and disposable products comprising single-use disposables and nasal interfaces.
